HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
25 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
MST1R
macrophage stimulating 1 receptor
Chromosome 3 · 3p21.31
NCBI Gene: 4486Ensembl: ENSG00000164078.15HGNC: HGNC:7381UniProt: B4E058
171PubMed Papers
21Diseases
4Drugs
1Pathogenic Variants
FUNCTIONAL ROLE
KinaseReceptor
RESEARCH IMPACT
Trending
CLINICAL
FDA Approved TargetOMIM Disease Gene
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionprotein bindingcell surfaceenzyme bindingnasopharyngeal neoplasmnon-small cell lung carcinomaneoplasmcancer
✦AI Summary

MST1R is a receptor tyrosine kinase located on chromosome 3 that transduces signals from extracellular ligands, primarily MST1, into cellular responses governing survival, migration, and differentiation. Upon ligand binding, MST1R undergoes autophosphorylation and recruits downstream effectors including PIK3R1, PLCG1, and GAB1, activating signaling cascades including RAS-ERK, PI3K-AKT, and PLCγ-PKC pathways 1. The receptor plays critical roles in wound healing through epithelial cell migration and proliferation, and in innate immunity by regulating macrophage migration and phagocytosis. MST1R dysfunction is implicated in multiple diseases. In cancer, MST1R is overexpressed in >80% of pancreatic cancers 2, where it accelerates progression through effects on both epithelial cells and tumor-associated macrophages. Similar roles exist in breast cancer, where RON/HGFL co-overexpression promotes tumorigenesis via autocrine and paracrine mechanisms 1. A FAK/c-MET/MST1R protein panel risk-stratifies colorectal cancer patients 3. MST1R also associates with nasopharyngeal carcinoma and melanoma progression 4. Beyond malignancy, MST1R variants contribute to premature ovarian insufficiency 5 and tetralogy of Fallot, where MST1R-deficient induced pluripotent stem cells differentiate into non-functional cardiomyocytes 6. Recent evidence identifies MST1R as a druggable target for osteoarthritis 7.

Sources cited
1
RON (MST1R) is a receptor tyrosine kinase activated by HGFL (MST1) ligand; RON activation involves autophosphorylation and recruitment of downstream signaling molecules; RON promotes proliferation, migration, and other cellular functions through MAPK and other pathways
PMID: 35626096
2
MST1R kinase is overexpressed in >80% of human pancreatic cancers; Mst1r overexpression accelerates pancreatic cancer progression by increasing acinar-ductal metaplasia and tumor-associated macrophage accumulation
PMID: 30967626
3
Co-overexpression of RON and HGFL in breast cancer promotes tumorigenesis through autocrine RON activation and paracrine activation of macrophage RON
PMID: 35626096
4
A combined FAK, c-MET, and MST1R three-protein panel can risk-stratify colorectal cancer patients and predict progression-free survival
PMID: 32739842
5
FOXC1 promotes melanoma by increasing MST1R expression and activating the PI3K/AKT pathway
PMID: 27533251
6
MST1R variants are associated with premature ovarian insufficiency and contribute to loss of ovarian function
PMID: 36732629
7
MST1R gene variants are associated with tetralogy of Fallot; MST1R-deficient induced pluripotent stem cells differentiate into non-functional cardiomyocytes
PMID: 40061823
8
MST1R is identified as a high-confidence druggable target for osteoarthritis through transcriptome-wide association study
PMID: 40079200
Disease Associationsⓘ21
nasopharyngeal neoplasmOpen Targets
0.62Moderate
non-small cell lung carcinomaOpen Targets
0.59Moderate
neoplasmOpen Targets
0.48Moderate
cancerOpen Targets
0.30Weak
multiple myelomaOpen Targets
0.28Weak
lung cancerOpen Targets
0.28Weak
Abnormality of the skeletal systemOpen Targets
0.22Weak
nasopharyngeal carcinomaOpen Targets
0.22Weak
type 2 diabetes mellitusOpen Targets
0.20Weak
diabetes mellitusOpen Targets
0.19Weak
inflammatory myofibroblastic tumorOpen Targets
0.19Weak
hypertensionOpen Targets
0.14Weak
health study participationOpen Targets
0.14Weak
essential hypertensionOpen Targets
0.13Weak
gastric cancerOpen Targets
0.12Weak
breast cancerOpen Targets
0.12Weak
prostate cancerOpen Targets
0.12Weak
denturesOpen Targets
0.09Suggestive
anaplastic large cell lymphomaOpen Targets
0.09Suggestive
urinary bladder carcinomaOpen Targets
0.09Suggestive
Nasopharyngeal carcinoma, 3UniProt
Pathogenic Variants1
NM_002447.4(MST1R):c.1477G>T (p.Asp493Tyr)Likely pathogenic
Multiple myeloma
☆☆☆☆2019→ Residue 493
View on ClinVar ↗
Drug Targets4
CRIZOTINIBApproved
EML4-ALK inhibitor
non-small cell lung carcinoma
GLESATINIBPhase II
Macrophage-stimulating protein receptor inhibitor
non-small cell lung carcinoma
MK-8033Phase I
Hepatocyte growth factor receptor inhibitor
NARNATUMABPhase I
Macrophage-stimulating protein receptor inhibitor
cancer
Related Genes
MST1Protein interaction100%EGFRProtein interaction98%HGFProtein interaction94%ERBB2Protein interaction92%CTNNB1Protein interaction91%HYAL2Protein interaction87%
Tissue Expression6 tissues
Lung
100%
Heart
34%
Ovary
15%
Liver
10%
Bone Marrow
10%
Brain
3%
Gene Interaction Network
Click a node to explore
MST1RMST1EGFRHGFERBB2CTNNB1HYAL2
PROTEIN STRUCTURE
Preparing viewer…
PDB4FWW · 1.85 Å · X-ray
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
0.98LoF Tolerant
pLIⓘ
0.00Tolerant
Observed/Expected LoF0.83 [0.71–0.98]
RankingsWhere MST1R stands among ~20K protein-coding genes
  • #2,580of 20,598
    Most Researched171 · top quartile
  • #883of 1,025
    FDA-Approved Drug Targets1
  • #4,752of 5,498
    Most Pathogenic Variants1
  • #9,430of 17,882
    Most Constrained (LOEUF)0.98
Genes detectedMST1R
Sources retrieved25 papers
Response time—
📄 Sources
25▼
1
Landscape of pathogenic mutations in premature ovarian insufficiency.
PMID: 36732629
Nat Med · 2023
1.00
2
PMID: 40061823
Phenomics · 2024
0.90
3
Targeting isoforms of RON kinase (MST1R) drives antitumor efficacy.
PMID: 37926711
Cell Death Differ · 2023
0.84
4
RON (
PMID: 35626096
Cancers (Basel) · 2022
0.80
5
The HNRNPA2B1-MST1R-Akt axis contributes to epithelial-to-mesenchymal transition in head and neck cancer.
PMID: 32669614
Lab Invest · 2020
0.72